Comparison of Diagnostic Accuracy of Luminal Index and MP MRI for Accelerated deTEction of Significant Prostate Cancer

Launched by UNIVERSITY COLLEGE, LONDON · Aug 18, 2021

Keywords

ClinConnect Summary

This clinical trial is comparing two different types of MRI scans to see which one is better at detecting significant prostate cancer. The standard method, called multi-parametric MRI (mpMRI), takes about 30-45 minutes to complete and is widely used, but it can sometimes miss important cancers. Researchers are looking at a new method called Luminal Index MRI (LI-MRI), which is faster—taking only about 10 minutes—and does not require a special contrast dye. The goal is to find out if LI-MRI can detect cancer more accurately than mpMRI.

To be eligible for the trial, men aged 65 to 74 who have been referred for a prostate MRI and believe they might have prostate cancer can participate. However, those with very high PSA levels, a previous prostate cancer diagnosis, or certain medical treatments that could interfere with the MRI will not be included. Participants can expect to undergo both types of MRI scans as part of the study, helping researchers learn more about the best ways to diagnose prostate cancer effectively.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men with clinically suspected prostate cancer and referred for prostate MRI
• • Willing and able to provide a written informed consent
• Exclusion Criteria:
• • Prostate specific antigen (PSA) level \> 20ng/ml within 6 months
• • Previous diagnosis of prostate cancer
• • Ongoing hormone treatment within 3 months prior to MRI, excluding antiandrogens or 5-alpha reductase inhibitors
• • Contraindication to MRI scan
• • Contraindication to administration of gadolinium-based contrast agents